Davis Todd C
SEC CIK 1392029 · EDGAR
BoughtSold
Most active insiders at LGND, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Espinoza Octavio | CFO | — | $13.03M |
| 2 | Reardon Andrew | CLO, Sec | — | $8.77M |
| 3 | Haas Jason | Dir | — | $3.74M |
| 4 | LAMATTINA JOHN L | Dir | — | $2.44M |
| 5 | Gray Nancy Ryan | Dir | — | $1.35M |
| 6 | Aryeh Jason | Dir | — | $1.25M |
| 7 | KOZARICH JOHN W | Dir | — | $1.20M |
| 8 | Sabba Stephen L | Dir | — | $1.16M |
| 9 | Zimmermann Martine | Dir | — | $342.0K |
| 10 | Davis Todd C | CEO, Dir | — | — |
Transactions 23
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-06 17:10 | 2026-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | J - Other | $160.71 | +132 | 199.5K | +0.1% | +$21.2K | |
| M | 2026-06-15 17:25 | 2026-06-11 | PTHS | Pelthos Therapeutics Inc. | Davis Todd C | Dir | P - Purchase | $27.82 | +35.9K | 75.8K | +90% | +$1000.0K |
| MA | 2026-04-01 17:45 | 2024-06-14+ | PTHS | Pelthos Therapeutics Inc. | Davis Todd C | Dir | A - Grant | $0.00 | +37.0K | 39.9K | +1,267% | $0 |
| D | 2026-03-27 | 2026-03-02 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +10.5K | 199.4K | +6% | $0 |
| M | 2026-02-18 | 2026-02-14+ | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | F - Tax | $183.83 | -32.9K | 198.0K | -14% | -$6.04M |
| M | 2026-02-18 | 2026-02-14 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +60.4K | 182.1K | +50% | $0 |
| 2025-12-08 | 2025-12-04 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | G - Gift | $0.00 | -130 | 161.3K | -0.1% | $0 | |
| DI | 2025-07-03 | 2025-07-01 | PTHS | Pelthos Therapeutics Inc. | Davis Todd C | Dir, 10% | C - Cnv Deriv | $10.00 | +1.50M | 1.50M | New | +$15.00M |
| 2025-07-02 | 2025-06-30 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | J - Other | $91.08 | +233 | 161.5K | +0.1% | +$21.2K | |
| M | 2025-05-13 | 2025-05-09 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | P - Purchase | $105.20 | +9,510 | 161.2K | +6% | +$1.00M |
| D | 2025-03-06 | 2025-03-04 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +21.4K | 151.7K | +16% | $0 |
| M | 2025-02-19 | 2025-02-14+ | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | F - Tax | $120.00 | -13.5K | 130.3K | -9% | -$1.61M |
| 2025-02-19 | 2025-02-14 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +20.8K | 143.8K | +17% | $0 | |
| 2024-08-09 | 2024-08-08 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | P - Purchase | $97.39 | +2,500 | 123.0K | +2% | +$243.5K | |
| 2024-07-02 | 2024-06-28 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | J - Other | $60.71 | +350 | 120.5K | +0.3% | +$21.2K | |
| DM | 2024-03-27 | 2024-03-25 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | M - OptEx | $57.39 | +16.0K | 120.2K | +15% | +$919.1K |
| D | 2024-02-29 | 2024-02-27 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +32.4K | 104.1K | +45% | $0 |
| D | 2024-02-23 | 2024-02-21 | PTHS | Pelthos Therapeutics Inc. | Davis Todd C | Dir | M - OptEx | $4.80 | +29.2K | 29.2K | New | +$140.0K |
| 2024-02-16 | 2024-02-15 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | F - Tax | $74.65 | -1,381 | 71.7K | -2% | -$103.1K | |
| 2023-09-25 | 2023-09-22 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | P - Purchase | $59.38 | +4,000 | 73.1K | +6% | +$237.5K | |
| 2023-06-13 | 2023-06-09 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | F - Tax | $73.76 | -420 | 69.1K | -0.6% | -$31.0K | |
| D | 2023-02-27 | 2023-02-23 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | CEO, Dir | A - Grant | $0.00 | +17.0K | 68.8K | +33% | $0 |
| D | 2022-06-13 | 2022-06-10 | LGND | LIGAND PHARMACEUTICALS INC | Davis Todd C | Dir | A - Grant | $0.00 | +1,004 | 51.8K | +2% | $0 |
Purchase Sale Sale after option exercise All abbreviations